Generalized Pairwise Comparisons to Assess Treatment Effects
Publié le
JACC Review Topic of the Week We are proud to share the most recent JACC “Review Topic of the Week” featured by the Journal of…
Minimization in randomized clinical trials
Publié le
Tutorial in Biostatistics – Statistics in Medicine IDDI has written a tutorial on Minimization in randomized clinical trials to be…
IDDI at Clinical Trials Strategic Summit EU 2023
Publié le
Meet IDDI’s expert from May 17-18 in London, UK at the 13th Clinical Trials Strategic Summit EU 2023! Schedule a…
ASCO 2023 – Meet IDDI Oncology Experts
Publié le
Schedule a meeting with Dr Marc Buyse, ScD and Dr Everardo Saad, MD at ASCO 2023 We will be happy…
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in HER2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–HER2 Therapy
Publié le
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Why do so Many Phase III Fail?
Publié le
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….
AN INNOVATIVE STATISTICAL METHODOLOGY
Publié le
Generalized Pairwise Comparisons – GPC Today’s session is focusing on an innovative statistical methodology called Generalized Pairwise Comparisons – or…
Integrating Technology and Expertise
Publié le
Phase I/II study in cancer patients showcases eClinical effectiveness. An Article written by IDDI Published in Applied Clinical Trials, February…
Assessing treatment efficacy in early-phase oncology trials
Publié le
Join IDDI experts to get updated on efficacy assessment in early-phase trials and more! ABSTRACT: One of the major recent…
Assessing activity in early-phase trials in oncology: current designs for expansion cohorts and phase 2
Publié le
Be updated on different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1…